Abstracts tagged "DMARDs"

Abstract Number: 036 • 2020 Pediatric Rheumatology Symposium
Medication Related Decision-Making in Parents of Children with Juvenile Idiopathic Arthritis
Alexandra Munroe¹, Adam Huber ², Bianca Lang ³, Suzanne Ramsey ⁴ and Elizabeth Stringer ⁴, ¹Dalhousie University, Halifax, Nova Scotia, Canada, ²IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ³Dalhousie University - Halifax, Halifax, Canada, ⁴IWK Health Centre, Halifax, Canada
Background/Purpose: Outcomes for juvenile idiopathic arthritis (JIA) have improved with use of disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Despite this, the decision by a parent…
Abstract Number: 137 • 2020 Pediatric Rheumatology Symposium
Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents
Chelsea DeCoste¹, Suzanne Ramsey ², Adam Huber ³, Bianca Lang ⁴ and Elizabeth Stringer ², ¹The Hospital for Sick Children, Toronto, Canada, ²IWK Health Centre, Halifax, Canada, ³IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ⁴Dalhousie University - Halifax, Halifax, Canada
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) and biologic agents are routinely used in the treatment of JIA and JIA-associated uveitis (JIA-AU). Parents are often fearful, however,…
Abstract Number: L08 • 2019 ACR/ARP Annual Meeting
Tapering of Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients in Sustained Remission: Results from a Randomized Controlled Trial
Siri Lillegraven¹, Nina Sundlisater ², Anna-Birgitte Aga ³, Joe Sexton ¹, Inge Christoffer Olsen ⁴, Hallvard Fremstad ⁵, Cristina Spada ⁶, Tor Magne Madland ⁷, Christian Høili ⁸, Gunnstein Bakland ⁹, Åse Lexberg ¹⁰, Inger Johanne Widding Hansen ¹¹, Inger Myrnes Hansen ¹², Hilde Haukeland ¹³, Maud-Kristine Aga Ljoså ¹⁴, Ellen Moholt ¹⁵, Till Uhlig ¹⁶, Daniel Solomon ¹⁷, Désirée van der Heijde ¹⁸, Tore Kvien ¹⁶ and Espen A Haavardsholm ¹⁵, ¹Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ²Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, ³Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, ⁴Oslo University Hospital, Oslo, Norway, ⁵Ålesund Hospital, Helse Møre og Romsdal, Ålesund, Norway, ⁶Lillehammer Hosptial for Rheumatic Diseases, Lillehammer, Norway, ⁷Haukeland University Hospital, Bergen, Norway, ⁸Hospital Østfold HF, Moss, Norway, ⁹University Hospital of North Norway, Tromsø, Norway, ¹⁰Drammen Hospital, Vestre Viken HF, Drammen, Norway, ¹¹Sørlandet Hospital HF, Kristiansand, Norway, ¹²Helgelandssykehuset Mo i Rana, Mo i Rana, Norway, ¹³Martina Hansens Hospital, Bærum, Norway, ¹⁴Ålesund Hospital Helse Møre og Romsdal HF, Ålesund, Norway, ¹⁵Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ¹⁷Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ¹⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Sustained remission is the goal of rheumatoid arthritis (RA) care, and more patients reach and maintain this state on conventional synthetic disease modifying anti-rheumatic…
Abstract Number: L01 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Yinzhu Jin ¹, Hemin Lee ¹, Moa Lee ², Joan Landon ³, Joseph Merola ⁴, Rishi Desai ⁵ and Seoyoung C. Kim¹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, ²University of North Carolina Chapel Hill, Chapel Hill, North Carolina, ³Brigham and Women's Hospital, Boston, Massachusetts, ⁴Harvard Medical School, Brigham and Women's Hospital, Boston, ⁵Brigham and Women's hospital, Boston
Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA)…
Abstract Number: 1420 • 2019 ACR/ARP Annual Meeting
Heterogeneity in the Pattern of Use of JAK-inhibitors Between Countries Participating in an International Collaboration of Registers of Rheumatoid Arthritis Patients (the JAK-pot Study)
Kim Lauper¹, Denis Mongin ², Sytske Anne Bergstra ³, Denis Choquette ⁴, Catalin Codreanu ⁵, Ori Elkayam ⁶, Kimme Hyrich ⁷, Florenzo Iannone ⁸, Eirik Kristianslund ⁹, Tore Kvien ¹⁰, Burkhard Leeb ¹¹, Galina Lukina ¹², Dan Nordström ¹³, Fatos Onen ¹⁴, Karel Pavelka ¹⁵, Manuel Pombo-Suarez ¹⁶, Ziga Rotar ¹⁷, Maria José Santos ¹⁸, Anja Strangfeld ¹⁹, Delphine Courvoisier ²⁰ and Axel Finckh ²⁰, ¹Division of Rheumatology, Geneva University Hospital, Switzerland / Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Geneva, Switzerland, ²Division of Rheumatology, Geneva University Hospitals, Switzerland, Geneva, Switzerland, ³Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, ⁵Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ⁶Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel, ⁷Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom / NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom, ⁸Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ⁹Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ¹⁰Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ¹¹Second Department of Medicine, Centre for Rheumatology Lower Austria, State Hospital Stockerau, Stockerau, Austria., Stockerau, Austria, ¹²V.A.Nasonova Research Institute of Rheumatology, Moscow, Russian Federation., Moscow, Russia, ¹³Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ¹⁴Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ¹⁶Rheumatology Service , Hospital Clinico Universitario , Santiago de Compostela , Spain., Santiago de Compostela, Spain, ¹⁷UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹⁸Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁹German Rheumatism Research Center (DRFZ), Berlin, Germany, ²⁰Division of Rheumatology, Geneva University Hospital, Switzerland, Geneva, Switzerland
Background/Purpose: In many countries, JAK-inhibitors (JAKi) have been recently accepted for the treatment of patients with rheumatoid arthritis (RA). However, prescription patterns may differ notably…
Abstract Number: 1518 • 2019 ACR/ARP Annual Meeting
Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases
Matthew Thomas ¹, Gavin Shaddick ², Rachel Charlton ¹, Charlotte Cavill ³, Richard Holland ⁴, Florenzo Iannone ⁵, Giovanni Lapadula ⁶, Simona Lapriore ⁵, Jakub Závada ⁷, Michal Uher ⁸, Karel Pavelka ⁹, Lenka Szczukova ¹⁰, Prodromos Sidiropolous ¹¹, Irini Flouri ¹¹, Burkhard Moeller ¹², Michael J. Nissen ¹³, Ruediger B. Mueller ¹⁴, Almut Scherer ¹⁵, Neil McHugh¹ and Alison Nightingale ¹, ¹University of Bath, Bath, United Kingdom, ²University of Exeter, Exeter, United Kingdom, ³Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, United Kingdom, ⁴Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵University of Bari, Bari, Italy, ⁶Rheumatology Unit – Department of Emergency and Organs Transplantation, University and AOU Policlinico of Bari, Italy., Bari, Italy, ⁷Institute of Rheumatology, Prague, Prague, Czech Republic, ⁸Institute of Health Information and Statistics of the Czech Republic, and Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic, ⁹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ¹⁰Masaryk University, Brno, Czech Republic, ¹¹University of Crete, Crete, Greece, ¹²University Hospital Bern, Bern, Switzerland, ¹³University Hospital Geneva, Geneva, Switzerland, ¹⁴Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, ¹⁵SCQM Foundation, Zürich, Switzerland
Background/Purpose: A large proportion of psoriatic arthritis (PsA) patients are prescribed a tumour necrosis factor inhibitor (TNFi) in combination with methotrexate (MTX), however the value…
Abstract Number: 1801 • 2019 ACR/ARP Annual Meeting
Comparison of Infection-Related Hospitalization Risk and Cost in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis Treated with Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Vardhaman Patel¹, Zulkarnain Pulungan ², Anne Shah ², Mahesh Kambhampati ², Francis Lobo ³ and Allison Petrilla ², ¹Bristol-Myers Squibb, New York City, NY, ²Avalere, washington, DC, ³Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: The risk and cost of infection-related hospitalizations in tumor necrosis factor inhibitors (TNFi)-experienced patients with rheumatoid arthritis (RA) receiving subsequent targeted disease-modifying antirheumatic drug…
Abstract Number: 1815 • 2019 ACR/ARP Annual Meeting
Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials
Nicolino Ruperto¹, Daniel J. Lovell ², John Bohnsack ³, Johannes Breedt ⁴, Michel Fischbach ⁵, Thomas Lutz ⁶, Kirsten Minden ⁷, Tatiana Miraval ⁸, Mahmood M. T. M. Ally ⁹, Nadina Rubio-Pérez ¹⁰, Elisabeth Gervais ¹¹, Riana van Zyl ¹², Robert Wong ¹³, Marleen Nys ¹⁴, Alberto Martini ¹⁵ and Hermine Brunner ¹⁶, ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ³University of Utah School of Medicine, Salt Lake City, UT, ⁴Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa, ⁵Pédiatrie 1, CHU Hautepierre, Strasbourg, France, ⁶Heidelberg University Hospital, Heidelberg, Germany, ⁷German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ⁸Clínica San Gabriel, Lima, Peru, ⁹University of Pretoria, Pretoria, South Africa, ¹⁰University Hospital Dr. José Eleuterio González, Monterrey, Mexico, ¹¹CHU de Poitiers, Rheumatology, Poitiers, France, ¹²University of the Free State, Bloemfontein, South Africa, ¹³Bristol-Myers Squibb, Princeton, ¹⁴Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹⁵IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹⁶Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: In EU, abatacept (ABA) with MTX is approved in patients (pts) with polyarticular-course JIA (pJIA), as young as 2 years (SC) and 6 years…
Abstract Number: 1861 • 2019 ACR/ARP Annual Meeting
Use of a Novel Electronic Auto-notification Process to Manage Transitions of Care in Rheumatic Patients on DMARD Therapy
Megan Bielawski¹, Eric Newman ² and Lisa Schroeder ¹, ¹Geisinger Medical Center, Danville, PA, ²Geisinger, Danville, PA
Background/Purpose: Effective communication is essential in caring for medically complex patients with rheumatologic diseases. In our prior study of rheumatoid arthritis patients and hospital admissions,…
Abstract Number: 194 • 2019 ACR/ARP Annual Meeting
Predicting Remission in Rheumatoid Arthritis: External Validation for Tocilizumab Monotherapy Using Corrona Real World Data
Fredrik Johansson¹, Jamie Collins ², Sara Gale ³, Hongshu Guan ⁴, Seoyoung C. Kim ⁵, Elena Losina ⁶, David Sontag ¹, Jacklyn Stratton ⁴, Huong Trinh ³, Jeffrey Greenberg ⁷ and Daniel Solomon ⁸, ¹MIT, Cambridge, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Genentech, San Francisco, CA, ⁴Brigham and Women's Hospital, Boston, ⁵Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁸Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Predicting remission in rheumatoid arthritis (RA) is an important goal for tailoring therapy. Tocilizumab (TCZ) has been found in randomized controlled trials (RCT) to…
Abstract Number: 1894 • 2019 ACR/ARP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Initiating Biologic and Non-biologic DMARDs, a Population-based Study
Lingyi Li¹, Na Lu ¹, Diane Lacaille ², Hui Xie ³, John Esdaile ⁴ and J. Antonio Avina-Zubieta ⁵, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, ⁴Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of venous thromboembolism (VTE, which includes pulmonary embolism [PE] and deep vein thrombosis [DVT]) compared…
Abstract Number: 250 • 2019 ACR/ARP Annual Meeting
Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Robin Dore¹, Jenya Antonova ², Chakkarin Burudpakdee ³, Lawrence Chang ², Jing He ⁴ and Mark Genovese ⁵, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³IQVIA, Falls Church, VA, ⁴IQVIA, Plymouth meeting, PA, ⁵Stanford University, Stanford, CA
Background/Purpose: For RA patients not meeting their treat-to-target goals despite treatment with their first biologic (b)DMARD, ACR guidelines recommend switching to a different bDMARD or…
Abstract Number: 2283 • 2019 ACR/ARP Annual Meeting
Improving Lactation Knowledge Among Providers Caring for Rheumatology Patients
Brooke Mills¹ and Bonnie Bermas ¹, ¹UT Southwestern Medical Center, Dallas, TX
Background/Purpose: While the benefits of breastfeeding for both the mother and her infant are well established, available resources regarding medication compatibility with lactation are limited. …
Abstract Number: 267 • 2019 ACR/ARP Annual Meeting
Develop Risk Prediction Model and Drug Withdrawl Road Map Through Pattern Extraction and Data Mining: Create a Master Algorithm from the Smart System of Disease Management (SSDM)
Yan Zhao¹, Xiaomei Li ², Rong Mu ³, Xiaoxia Zuo ⁴, Hua Wei ⁵, Lingli Dong ⁶, Shouxin Li ⁶, Hongsheng Sun ⁷, Guanmin Gao ⁸, Lijun Wu ⁹, Bing Wu ¹⁰, Yuhua Jia ¹¹, Hui Xiao ¹², Minghua Xu ¹³, Wenyu Zhou ¹⁴, Aichun Chu ¹⁵, Li Dong ¹⁶, Huiqin Yang ¹⁷, Ming Gui ¹⁸, Weiqi Min ¹⁹, Zhenchun Zhang ²⁰, Ying Pan ²¹, Junli Zhang ²², Jinchang He ²³, Haiying Chen ²⁴ and Fei Xiao ²⁵, ¹Peking Union Medical College hospital, Beijing, Beijing, China (People's Republic), ²the First Affiliated Hospital of University of Science and Technology of China, Hefei, China (People's Republic), ³People's Hospital, Beijing University Medical School, Beijing, China (People's Republic), ⁴Xiangya Hospital Centeral South University, Changsha, China (People's Republic), ⁵Northern Jiangsu People's Hospital, Yangzhou, China (People's Republic), ⁶Tongji Hospital，Tongji Medical Colllege，Huazhong University of Science and Technology, Wuhan, Hubei, China (People's Republic), ⁷Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China (People's Republic), ⁸the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic), ⁹People's Hospital of Xinjiang Uygur Autonomous region, Wulumuqi, Xinjiang, China (People's Republic), ¹⁰Shanghai Gothic Internet Technology Co., Ltd, Shanghai, China (People's Republic), ¹¹Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹²Shanghai Gothic Internet Technology Co., Ltd, shanghai, Shanghai, China (People's Republic), ¹³Affiliated Hospital of Hebei University, Baoding, China (People's Republic), ¹⁴WuHan Fourth Hospital, Wuhan, China (People's Republic), ¹⁵Hubei general hospital, Wuhan, China (People's Republic), ¹⁶Jingzhou Central Hospital, Jingzhou, China (People's Republic), ¹⁷Wuhan NO.1 Hospital, Wuhan, China (People's Republic), ¹⁸The third xiangya hospital of central south university, Changsha, China (People's Republic), ¹⁹Heze municipal hospital, Heze, China (People's Republic), ²⁰Linyi People's Hospital, Linyi, China (People's Republic), ²¹the First Affiliated Hospital of xi'an Jiaotong University, Xi'an, China (People's Republic), ²²Xi'an Fifth Hospital, Xian, China (People's Republic), ²³Panzhihua Central Hospital, Panzhihua, China (People's Republic), ²⁴The Third Hospital of Hebei Medical University, Shijiazhang, China (People's Republic), ²⁵Shanghai Gothic Internet Technology Co., Ltd., shanghai, China (People's Republic)
Background/Purpose: Combination therapy with DMARDs for treating RA is considered as a standard of care. However, certain rates of adverse events (AEs) are unavoidable. The…
Abstract Number: 2366 • 2019 ACR/ARP Annual Meeting
Comparison of Healthcare Resource Utilization (HCRU) and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Switch to Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Vardhaman Patel¹, Zulkarnain Pulungan ², Anne Shah ², Barton Jones ², Allison Petrilla ², Leticia Ferri ³, Xue Han ³ and Kaleb Michaud ⁴, ¹Bristol-Myers Squibb, New York City, NY, ²Avalere, washington, DC, ³Bristol-Myers Squibb Company, Princeton, NJ, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with RA experienced an increase in the whole-body insulin sensitivity and a reduction in HbA1c levels from treatment with abatacept, which is a…

1
2
3
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].